Drug Profile
Flecainide inhalation - InCarda Therapeutics
Alternative Names: Flecainide acetate inhalation solution; FlecIH-101; FlecIH-103; FlecIH-104; Inhaled flecainide - InCarda Therapeutics; InRhythm™Latest Information Update: 19 Jun 2023
Price :
$50
*
At a glance
- Originator InCarda Therapeutics
- Class Benzamides; Class Ic antiarrhythmics; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Paroxysmal atrial fibrillation
Most Recent Events
- 09 Jun 2023 InCarda Therapeutics terminates the Phase-III RESTORE-1 clinical trial in Paroxysmal atrial fibrillation (Newly diagnosed) in USA, Spain, Poland, Hungary, Czech Republic, Netherlands (Inhalation, Liquid) due to limited efficacy upon blinded review (NCT05039359) (EudraCT2021-001627-40)
- 12 Dec 2022 Phase-I development is ongoing in Australia for Paroxysmal atrial fibrillation (In volunteers) (Inhalation) (ACTRN12620000461998)
- 26 Aug 2022 Efficacy data from a phase II trial in Paroxysmal atrial fibrillation presented at theannual congress of the European Society of Cardiology (ESC-Card-2022)